Today: 11 June 2026
Petrobras stock (PBR) slips as oil falls; Tupi hits 1 million bpd, fertilizer restart in focus
15 January 2026
1 min read

Petrobras stock (PBR) slips as oil falls; Tupi hits 1 million bpd, fertilizer restart in focus

Rio de Janeiro, Jan 15, 2026, 12:45 BRT — Regular session

Petrobras’ shares listed in the U.S. slipped Thursday, despite the Brazilian oil giant highlighting new operational progress at its key offshore fields.

Petróleo Brasileiro S.A. – Petrobras is heavily dependent on volume. Production from the pre-salt—deepwater reserves buried beneath a thick salt layer—has powered earnings and dividends lately, and traders react swiftly to any sign that this growth is slowing.

Petrobras is also pressing forward with another venture: fertilizers. The timeline for reviving its urea and ammonia plants in Brazil’s northeast has turned into a subtle yet telling sign of how far the company’s leadership is willing to extend beyond its core oil and gas operations.

Energy stocks pulled back as crude prices dropped from recent highs. Brent crude fell roughly 3.3% to $64.34 a barrel, according to Reuters data. In U.S. trading, Exxon slipped about 0.8%, Chevron declined near 0.8%, and TotalEnergies was down around 1.4%.

Petrobras’ ADRs (PBR) slipped roughly 1.1%, closing at $12.52.

CEO Magda Chambriard told Reuters this week that Petrobras has hit a production rate of one million barrels per day (bpd) at the offshore Tupi field since Friday, describing it as “the rescue of a symbol for Brazil.” She also noted Petrobras now operates two giant fields, Tupi and Buzios, each with the potential to exceed 1 million bpd. In 2025, the company connected 11 wells to production vessels at Tupi and is evaluating the addition of a floating production vessel there by 2031. Baird Maritime / Work Boat World

Petrobras is gearing up to restart fertilizer production after years offline. The company said the FAFEN-SE plant in Sergipe resumed ammonia output on Dec. 31, followed by urea production on Jan. 3. Meanwhile, urea production at the FAFEN-BA plant in Bahia is set to resume by month’s end. Together, these two plants cover about 12% of Brazil’s urea demand, Petrobras said.

Petrobras announced in a separate filing that its 2026 annual general meeting will take place on April 16. Details on the time, location, and format will be provided at a later date.

The company’s corporate calendar indicates that investors will receive the next solid update on cash flow and shareholder returns when Petrobras releases its full annual financial statements for 2025 on March 5. An investor and analyst call is scheduled for March 6 to discuss the results.

The road ahead isn’t smooth. Petrobras is still vulnerable to oil price volatility, and geopolitical shifts can easily overshadow any company gains. In Brazil, environmental and regulatory hurdles add to the challenge, notably in the Foz do Amazonas basin, where the oil regulator has paused drilling after a synthetic-fluid spill.

Traders are focused on whether Petrobras can keep up the 1 million bpd output at Tupi and meet the end-January deadline for Bahia’s fertilizer restart. The bigger milestone arrives March 5, when Petrobras releases its annual results and management fields questions on dividends, spending, and production goals.

Stock Market Today

  • Aurinia Pharmaceuticals (AUPH) Valuation Update Amid Share Price Stability
    June 11, 2026, 11:12 AM EDT. Aurinia Pharmaceuticals (NasdaqGM:AUPH) shares closed at $15.66, showing modest consolidation after recent gains. The 90-day return stands at 8.98%, contrasting with a strong 93.57% gain over the past year. The company reported revenue of $298.3 million and net income of $298.2 million. Analysts estimate the stock is undervalued by about 7.9%, with a fair value of $17.00. Key growth drivers include its lead drug, aritinercept, targeting autoimmune diseases with ongoing Phase I success and upcoming trials. Risks involve patent challenges to LUPKYNIS and potential trial delays. Investors are advised to consider these factors alongside broader healthcare AI opportunities. Simply Wall St's analysis highlights cautious optimism on Aurinia's growth potential amid evolving market dynamics.

Latest articles

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

Theriva Biologics Pops on VCN-01 Study Results, Gets Traders’ Attention

11 June 2026
TOVX soared 74.6% to $0.4252 after Theriva Biologics published Phase 1 VCN-01 data showing survival and biomarker signals in head-and-neck cancer, but the jump was not due to drug approval or revenue; investors face ongoing financing, dilution, and clinical-trial execution risks, with the company’s cash runway only into Q1 2027 and substantial doubt about its ability to continue as a going concern without new capital.
Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

Trulieve Stock Turns Heads on NYSE After $50 Million Buyback

11 June 2026
Trulieve began NYSE trading as TRLV this week after moving from OTC/CSE, authorized a buyback of up to $50 million or 8.5 million shares, and closed its first NYSE session at $11.50, down 0.43%, before trading near $11.78 early Thursday, as investors weigh whether the uplisting and buyback will boost demand amid ongoing federal cannabis policy uncertainty.
Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

Propanc Biopharma Jumps on $5 Million Buyback Plan, Investors React

11 June 2026
Propanc Biopharma shares soared as much as 392% after authorizing up to $5 million in stock buybacks—exceeding its prior $3.1 million equity value—even as it reported just $443,702 in cash and flagged going-concern risks, with investors now focused on whether its lead cancer drug PRP will advance to a planned Phase 1b trial this year.
POET Technologies stock climbs before the bell as call-option volume spikes
Previous Story

POET Technologies stock climbs before the bell as call-option volume spikes

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Next Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Go toTop